Promising therapies for treatment of nonalcoholic steatohepatitis.

ABSTRACT:

Introduction

Non-alcoholic fatty liver disease (NAFLD) has become the most common etiology for abnormal aminotransferase levels and chronic liver disease. Its growing prevalence is largely linked to the presence of metabolic syndrome, particularly diabetes and insulin resistance. It is estimated that 60-80% of the type 2 diabetic population has NAFLD. NAFLD encompasses a range of conditions ranging from simple steatosis to non-alcoholic steatohepatitis (NASH). A subset of patients with hepatic steatosis progress to NASH, while 15-20% of patients with NASH develop cirrhosis. This progression is thought to be multifactorial, and there are currently no FDA-approved medications for the treatment of NASH.

Areas covered

We review drugs currently in Phase II and III clinical trials

SUBMITTER: Noureddin M 

PROVIDER: S-EPMC5906104 | biostudies-literature | 2016 Sep

REPOSITORIES: biostudies-literature